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ABSTRACT 
 Respiratory infectious diseases are among the leading cause of morbidity and mortality in 
the world. This paper presents two respiratory diseases, Mycobacterium bovis and Streptococcus 
pneumoniae, which cause significant global health issues despite the advancement of vaccines.  
 In Uganda, M. bovis isolates (n=27) were PCR-tested for a specific chromosomal deletion 
(RDAf2) and spoligotyped for specific characterization of the Af2 clonal complex. Seventeen 
(63%) isolates contained the Af2 clonal complex. The high prevalence indicates Af2 clonal 
complex is of epidemiological interest and a likely cause of bovine tuberculosis in Kampala, 
Uganda. 
Ten vervet serum (varying age groups) levels were measured (Luminex) for the 
immunoglobulin G (IgG) antibody response against the 23-valent, Pneumovax 23® (PN23), 
pneumococcal capsular polysaccharide serotypes when simultaneously administered with F1/V 
plague vaccine and Influenza vaccine. Subjects 9-11 years and 25-26 years have shown a slightly 
better immune response (11%) to PN23 serotypes compared to 19-23 year subjects. 
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CHAPTER 1. INTRODUCTION 
The ‘One Health - One World’ concept is described as the synergistic relationship 
between the health of the environment, livestock, and humans (15). In recent years, many 
multidisciplinary health professionals have collaborated to address the ‘One Health – One Word’ 
concept in an effort to understand the multitude of infectious disease (15). These include 
emerging infectious diseases (EIDs) and re-emerging (resurging) infectious diseases (RIDS) 
(15). With a vast amount of genetic microbial diversity associated with infectious disease (i.e. 
zoonotic, vector-borne, water-borne, air-borne), it is imperative to understand the complex 
interplay between host structure(s), pathogen, and environment in order to raise awareness, to 
sustain, and to prevent EIDs, and RIDs (10, 25, 31).  An estimated 15 million deaths result 
annually from infectious diseases worldwide, rivaling war and famine, not including mortalities 
from progressive and chronic diseases associated with infections (10, 25). Despite best efforts, 
EIDs and RIDs continue to challenge public health systems throughout the world as the dynamic 
host-pathogen interplay continues to evolve into new and advantageous ecological conditions 
(10, 25, 31).  
Emerging and resurging infectious diseases are frequent and more devastating in 
developing countries, causing significant public health, as well as hindering the economic growth 
and increasing the likelihood of a poverty trap (7, 25). Many factors that vary with poor 
surveillance and treatment may lead to epidemics and pandemics (13, 25). These factors include 
environmental change (i.e. earthquakes, floods, droughts), climate anomalies, poor sanitation, 
host-agent interactions, overcrowding and urbanization, diet and nutrition, failure of social 
cohesion, genetic mutations, the genetic composition of the population, drug resistance, and 
zoonosis (13, 25, 31). The resources to monitor, control, and prevent EID and RID outbreaks are 
limited or nonexistent in much of the developing world (3, 4, 7, 11, 25).  
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My project at the Department of Medical Microbiology, College of Health and Sciences, 
Makerere University in Kampala, Uganda allowed me to study the significance of zoonotic 
Mycobacterium bovis and its impact upon everyday life. Zoonotic infections alone account for 
over 60% of the world’s EIDs and play a major role in RIDs (13, 25, 31).  With limited 
awareness, surveillance, and diagnosis in developing countries, M. bovis contributes to an 
unknown prevalence of zoonotic tuberculosis globally. 
My second project was at the United States (US) Centers for Disease Control and 
Prevention (CDC) in Atlanta, Georgia. This experience provided me with the opportunity to 
study the immunological effects of simultaneous vaccine (F1/V plague vaccine and Influenza 
[Flu] vaccine) administration upon multivalent pneumococcal vaccine, Pneumovax 23® (PN23), 
using a simian model. PN23 is one of the most important and frequently administered vaccines 
for Streptococcus pneumoniae in high-risk populations (children, the immunodeficient, and the 
elderly) worldwide. It is pertinent to understand the effect of multiple vaccines and treatments 
when developing and enhancing disease surveillance and control methods.  
Tuberculosis and S. pneumoniae are among the most common and life threatening 
respiratory diseases throughout the developing world. Within the last couple decades, respiratory 
diseases have become more frequent in developing countries. International trade and travel 
possibly contribute to the more frequent infections. Further research of disease surveillance and 
vaccine development is pertinent to successfully manage and treat EIDs and RIDs throughout the 
world. 
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CHAPTER 2. PREVALENCE OF AFRICAN 2 CLONAL COMPLEX (Af2) 
IN MYCOBACTERIUM BOVIS ISOLATES FROM BOVINE TISSUE IN 
KAMPALA-UGANDA, AFRICA 
Abstract 
A collection of twenty-seven Mycobacterium bovis samples from bovine tissues was 
characterized to determine the prevalence of the African 2 (Af2) clonal complex of 
Mycobacterium in Kampala, Uganda to further determine strain pathogenicity, communicability, 
and infectivity. Samples were analyzed using PCR for specific chromosomal deletion (RDAf2) 
and typed by spoligotyping (spacer oligonucleotide typing), a PCR and hybridization technique, 
for specific characterization. Af2 clonal complex is characterized by a deleted RDAf2 locus and 
absence of spoligotype spacers 3 to 7. Of all isolates, 63% contained the Af2 clonal complex; of 
which, 53% were characterized by the spoligotype strain SB0133 and 47% SB1407. Of the 37% 
of isolates negative for Af2, the largest cluster (60%) was characterized by the spoligotype strain 
SB1405. The high prevalence of the Af2 clonal complex within the M. bovis samples is a likely 
cause of increased transmission and infection within cattle in Kampala, Uganda. 
Introduction 
Mycobacterium bovis is the causative agent of bovine tuberculosis (BTB). BTB is 
prevalent in cattle among developing countries such as Uganda, Tanzania, and much of western 
Africa (3, 4, 11). M. bovis causes zoonotic infections in humans from the ingestion of 
unpasteurized milk from infected cattle or the inhalation of the organism from infected 
aerosolized droplets (11, 38).   
Animal BTB surveillance and treatment programs in developing countries are insufficient 
or nonexistent which contributes to the poor amount of data regarding BTB-infected cattle and 
zoonotic infections to humans (11). It is important to identify the strains of M. bovis in order to 
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determine if a specific strain has increased infectivity, communicability, and virulence between 
and in host populations. This study characterized 27 M. bovis samples to determine the 
proportion of the Af2 clonal complex and spoligotype strains within the collection. 
A recent report in eastern Africa indicates the presence of a unique clonal complex of M. 
bovis named African 2 (Af2) from cattle in Uganda, Burundi, Tanzania, and Ethiopia (3, 4). The 
Mycobacterium tuberculosis complex (MTC) is made up of five species including M. bovis, M. 
africanum, M. microti, M. canetti and M. tuberculosis (3, 4, 11, 17). The genomes within the 
MTC are highly homologous due to the nonexistent chromosomal DNA exchange across the 
species within the complex (3, 4, 11, 17). The study found 11 isolates of M. bovis from a 
collection of 87 MTC samples, six of which belonged to the Af2 clonal complex (3, 4). The high 
incidence rate of BTB and the high levels of genetic exchange between strains are likely due to 
Kampala’s close proximity to the Ugandan Cattle Corridor (UCC), the large number of dairy 
cattle (cross/grade cattle) within the city, and the high human density (Figure 1). 
Literature Review 
Mycobacterium bovis 
 Mycobacterium is rod shaped, aerobic, infectious, and pathogenic bacteria (14). As with 
all Mycobacterium species, M. bovis is characterized by a cell wall composed in part by mycolic 
acid. The high-lipid mycolic acid results in a positive acid-fast reaction. The organism is the 
causative agent for BTB in cattle as well as zoonotic TB in humans (3, 14). M. bovis has a slow 
generation time (16-24 hours) and infects the host through latent infection (3, 4, 20). M. bovis 
also is known to infect other warm-blooded mammals (i.e. deer, bison, lions, badgers, and 
swine), causing an approximated annual loss of $3 billion to Agriculture worldwide (14). The 
actual number is estimated to be higher due to the limited BTB surveillance and treatment 
programs throughout the world (3, 14). 
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Clinically, M. bovis cause symptoms similar to M. tuberculosis (MTB) and include night-
sweats, coughing, chronic invigoration, emaciation, granulomas, bacteremia, and vertebral 
osteomyelitis (Pott’s Disease) (1, 14). Additionally, the genome of M. bovis is >99.52% identical 
to M. tuberculosis (14). Extrapulmonary infection occurs in humans when an infected animal, 
with a mycobacterial mastitis infection, sheds the bacteria in the milk that is then consumed by 
humans without pasteurization (3, 14). Pulmonary infection can also occur through the inhalation 
of infected aerosol droplets (3, 14). Due to the small number of documented cases of BTB 
throughout the world, frequently do not receive the correct treatment because of misdiagnosis, 
increasing the risk of sever disease (3, 14). A recent study in the United States found that BTB-
infected individuals have a higher death rate compared to MTB-infected individuals (20). 
Additionally, the study indicated that individuals co-infected with both HIV and BTB have a 
significantly higher death rate compared to individuals infected with only HIV or BTB (20). The 
high death rates associated with BTB may be attributed to the organism’s resistance to 
pyrazinamide, a short-term antibiotic regimen (6 months) used along with other antibiotics to 
treat MTB (20). However, since M. bovis is resistant to pyrazinamide, the therapy regimen must 
be lengthened (approximately 94 days longer) (20). Without the correct regime, BTB-infected 
humans have an increased likelihood of developing sever complications and disease (20). 
  To date, the M. bovis bacilli Calmette-Guérin (BCG) vaccine has been the most widely 
used prophylactic throughout the world to prevent BTB and MTB (19). Despite the advances in 
vaccine technology and administration of the BCG vaccine, TB still remains one of the leading 
causes of death from infectious diseases worldwide (19). The high mortality rate from TB is in 
part due to the inconsistent vaccine efficacy and diagnostic limitations in developing countries. 
BCG efficacy varies from 0% to 80%, which is dependent on geographical location, climate, 
causative agent, strain variance, administration, and the age of the individual upon vaccination 
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(8, 19). Unfortunately, vaccine efficacy is low and supplies scarce in populations that need the 
BCG vaccine and treatment the most (i.e. developing countries, tropical regions, 
immunocompromised people, and the elderly) (8, 19). The low vaccine efficacy within these 
populations is likely due to frequent exposure to nontuberculosis Mycobacterium species (8). 
Furthermore, M. bovis is less responsive to the BCG vaccine compared to M. tuberculosis (8). 
With such a wide range in efficacy and the high levels of morbidity and mortality due to TB in 
the world, additional research is vital for the prevention and treatment of zoonotic and non-
zoonotic TB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
Figure 1.  Map of the Ugandan Cattle Corridor and Dairy Cattle Ownership in Uganda. 
Dairy cattle ownership is characterized by the number of households with cross/grade dairy 
cattle (30% - 45%) (3, 22). Map courtesy of National Geographic Education. National 
Geographic does not review or endorse content added to this background by others.  
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Spoligotyping Assay 
Spacer oligonucleotide typing (spoligotyping), first described by Kamberbeek et al. 
(1997) is a rapid polymerase chain reaction (PCR)-based method used to differentiate and 
characterize Mycobacterium species from collected samples without having to grow the bacteria 
(3, 4, 17).  This method uses 43 unique spacer sequences, specific to the MTC, in the repetitive 
direct repeat (DR) region of the mycobacterium locus to differentiate and characterize collected 
samples by the hybridization of biotinylated denatured DNA (3, 4, 17). The DR region of the 
locus contains conserved 36bp DRs with non-conserved 34 to 41bp spacer sequences located 
between the DRs (17). These unique non-conserved spacer sequences between the DRs are 
hybridized to the membrane of the miniblotter, yielding a positive spacer sequence if hybridized 
to the corresponding covalently, membrane-bound oligonucleotide sequence (3, 17). The 
spoligotype patterns are crosschecked against an online spoligotype database using binary code 
to characterize the sample; sample SB0133 yields the binary code 
[1100000101111110111111111111111111111100000] (3, 17). M. bovis samples are 
characterized with spacers 39 to 43 absent (17). 
The Af2 clonal complex is characterized by the absence of spoligotype spacers 3 to 7 as 
well as the presence of the chromosomal RDAf2 deletion (3, 4). A multiplex PCR method was 
used to determine the RDAf2 deletion. The multiplex PCR uses three primers (RDAf2_Fw, 
RDAf2_Rev, and RDAf2_IntRev), which yields either the presence of the RDAf2 (458bp) or 
deletion of the RDAf2 (707bp) between the Mb0599 and Mb0610 of the chromosome (3, 4). The 
RDAf2 method is similar to Nested PCR where the target DNA sequence is internally reversed 
synthesized with the first product produced resulting in a smaller bandwidth (458bp) (3, 4). 
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Materials and Methods 
Mycobacterium Isolates 
The Department of Medical Microbiology, College of Health Sciences at Makerere 
University in Kampala-Uganda, collected, processed, and supplied the twenty-seven purified 
DNA samples from various cattle lesions. The International Foundation for Sciences (IFS) 
provided funds for the Mycobacterium sample collection.  
PCR Parameters 
Initial denaturation step was 15 min at 96°C, 35 cycles of 30 s at 96°C, 30 s at 55°C, and 
1 min at 72°C, followed by a final elongation step of 10 min at 72°C (3). PCR products were 
separated on an ethidium bromide-stained 1% agarose gel at 120V for one hour against a Hi-Lo 
DNA marker (3). The gel was analyzed using a BioDoc-IT 220UV Gel Imaging Workstation 
(Ultra Violet Products, Upland, CA) transilluminator. 
RDAf2 Screening 
PCR mixture contained 2µl of supernatant of heat-killed mycobacteria, 10µl of 1X 
HotStartTaq master mix (Qiagen, Valencia, CA), 0.3µl primers RDAf2_FW (5’-
ACTGGACCGGCAACGACCTGG-3’), RDAf2_Rev (5’-CGGGTGACCGTGAACTGCGAC-
3’), and RDAf2_IntRev (5’-CGGATCGCGGTGATCGTCGA-3’) (primer set Af2) (provided by 
Mulago Hospital, Kampala, Uganda), and sterile distilled water to a final volume of 20µl (3).  
Spoligotyping 
Processed samples were spoligotyped according to the method of Kamerbeek et al. 
(1997) using a commercialized kit with Drb (5’-CCGAGAGGGGACGGAAAC-3’) and 
biotinylated-Dra primers (5’-GGTTTTGGGTCTGACGAC-3’) (Isogen Bioscience BV, 
Maarssen, The Netherlands) according to thermal cycler parameters (3, 17).  Denatured biotin-
labeled M. bovis PCR samples were hybridized onto a membrane containing 43 covalently bound 
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spacer sequences in a miniblotter system (Miniblotter 45; Immunetics, Cambridge, Mass.) (3).  
Spoligotype patterns were exposed using chemiluminescence (3). 
Data Analysis 
Spoligotype patterns were compared with those existing in the International 
Mycobacterium bovis database at www.mbovis.org/spoligodatabase/singlpattern.php 
Results  
Distribution of RDAf2 Among Cattle Isolates in Kampala 
Multiplex PCR was used to analyze all 27 M. bovis isolates for the presence of RDAf2 
deletion (3). The RDAf2 deletion was identified by a 707 bp band in the PCR gel and missing 
spacers 3 to 7 in the spoligotype pattern as shown in Fig 1 and Fig 4, respectively (3). SB1033 
and SB1407 spoligotype patterns accounted for 17 out of 27 (63%) of the sample (3).   
Spoligotyping Results 
Five different spoligotype patterns were identified among the 27 M. bovis samples 
collected from cattle lesions (Figure 4).  All spoligotype patterns were previously documented in 
the online spoligotype database at www.mbovis.org/spoligodatabase/singlpattern.php. The 
identified spoligotypes were strain SB1033, observed for nine samples (33%); strain SB1407 
observed for eight samples (29%); strain SB1405 observed for six samples (22%); strain SB1404 
observed for two samples (7%); and strain SB0134 for one sample (3%). The most prevalent 
spoligotype strains SB0133 and SB1407 (63%) had spacers 3 to 7, 9, 16, and 39-43 absent, with 
strain SB1407 with additional spacers 19 to 22 absent.  
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Figure 2. RDAf2 Deletion Multiplex PCR. 
Multiplex PCR with primers specific for Mycobacterium bovis RDAF2 deletion (707bp) or insertion (458bp) detection. Lane M, is the 
molecular weight marker. M. bovis Af2122/97 (RDAf2 Intact), M. bovis Burundi (RDAf2 Deleted), and negative water used as Controls. 
The presence of the deletion of RDAf2 (14.1 kb between Mb0599 and Mb0610) is the definition of Af2 clonal complex (3, 4). 
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Figure 3. Schematic Representation of Direct Repeat Region of Mycobacterium Locus. 
(A) Structure of the Direct Repeat region of the mycobacterium locus. (B) DR region depicted as rectangles with corresponding unique 
spacer oligonucleotides numbered 21-30. The IS6110 copy is inserted within the 36-bp DR locus of the majority of strains. (C) Principle 
in vivo amplification of fragments using Dra (a) and Drb (b) primers. The ordered spacers correspond to the spoligotype pattern. 
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Figure 4. Schematic Representation of Spoligotype of Mycobacterium bovis Isolates. 
Schematic representation of the spoligotypes of 26 clustered M. bovis strains.  Spoligotype pattern is shown as a series of 43 spacer 
sequences. Filled rectangles representing positive hybridization of biotinylated-PCR samples, and empty rectangles indicating lack of 
hybridization (3, 4). Absence of spacers 3-7 represents Af2 clonal complex (3, 4). Isolate 6618 is not shown.  
12 
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Discussion 
Developing countries have limited disease surveillance and identification strategies to 
differentiate M. tuberculosis and M. bovis causing human TB (3). Identification and 
characterization of samples collected from cattle lesions can attribute to disease surveillance as 
well as help identify zoonotic public health and agricultural concerns among the population, 
leading to increased awareness (3, 11). In Kampala-Uganda, one of the most densely populated 
cities, the interface between cattle and humans is high due to the agriculturally dominant way of 
living, traditional practices, and human social life (3, 11). These factors are in part increasing the 
risk of BTB exposure among host populations (3, 11). Additionally, occupational hazards also 
contribute to the unknown prevalence of zoonotic BTB among developing countries. Ranchers, 
traditional farmers, veterinarians, and butchers are among some of the most common occupations 
that are at increased risk for developing BTB as well as other zoonotic diseases (3, 11).  
 In Kampala, a study of 27 M. bovis samples from cattle lesions revealed five different 
spoligotype strains, which may be due to the genetic diversity of M. bovis or the exposure to 
various strains in the cattle corridor (3). Of the five strains, we have found two Af2 strains 
SB1033 and SB1407 yielding sixty-three percent of the samples. We have determined that the 
high prevalence of Af2 strains (SB1033 and SB1407) indicate increased strain pathogenicity. 
The remaining three non-Af2 strains consist of SB0134, SB1404, and SB1405.  
With the high prevalence of the Af2 clonal complex among BTB, we can conclude that 
Af2 is of epidemiological importance in the disease surveillance of zoonotic infectious diseases 
within Kampala, Uganda. Future studies might seek to further understand the prevalence of 
specific M. bovis strains between human and cattle zoonotic tuberculosis cases in Kampala, 
Uganda as well as determine the infectivity rate of Af2 strains for the advancement of 
tuberculosis vaccine and treatment. 
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CHAPTER 3. THE MEASUREMENT OF IMMUNOGLOBULIN G 
ANTIBODY PRODUCTION OF A 23-VALENT, PNEUMOVAX 23®, 
PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE 
SIMULTANEOUSLY ADMINISTERED WITH F1/V PLAGUE VACCINE 
AND INFLUENZA VACCINE: USING A NON-HUMAN (VERVET 
MONKEY) MODEL 
Abstract  
Streptococcus pneumoniae is one of the leading causes of respiratory-associated death in 
the world among high-risk populations. A 23-valent, PN23, pneumococcal capsular 
polysaccharide (PnPs) vaccine is one of the most predominately administered anti-capsular 
pneumococcal immunoglobulin G (IgG) antibody vaccines in the world.  The efficacy and 
immune response to individual PN23 serotypes (ST) vary significantly. We simultaneously 
(multiplexed Luminex immunoassay) measured (pre- and post-vaccination) the IgG immune 
response to each 23 PnPs STs (i.e. ST 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20 22F, 23F, and 33F) when simultaneously vaccinated with two high 
efficacy vaccines; F1/V plague vaccine and Flu vaccine. Using simian models with varying age 
distributions 9-11 years (n=5), 19-23 years (n=3), and 25-26 years (n=2). All animals had an 
increase in IgG response to ≥3 PnPs STs after vaccination. Three animals (30%) mounted an 
immune response to ≥3 - ≥10 PnPs; seven (70%) mounted an immune response to >10 PnPs STs; 
and one (10%) mounted an immune response to all 23 PnPs serotypes. Of all the serotypes, nine 
(39.1%) PnPs STs (ST4, ST7F, ST8, ST9N, ST11A, ST15B, ST17F, ST19F, and ST20) mounted 
a robust immune response in five or more subjects. One or more subjects in the 9-11 age group 
responded to all 23 (100%) PnPs STs, subjects in the 19-23 age group responded to 17 (73.9%) 
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PnPs STs, and subjects in the 25-26 age group responded to 18 (78.2%) PnPs STs. Age groups 9-
11 and 25-26 displayed slightly higher immune responses compared to the 19-23 age group. 
Introduction 
 Streptococcus pneumoniae (pneumococcus) is a Gram-Positive pathogen that 
asymptomatically colonizes in the nasopharynx of humans, the only known natural reservoir (36, 
37). Pneumococcus is an opportunistic pathogen the can cause severe disease once it enters into 
the blood stream (24, 27, 36). Pneumococcus is the causative agent of Invasive Pneumococcal 
Diseases (IPDs) such as pneumonia, otitis media, meningitis, bacteremia, and sepsis (24, 27, 36). 
Each year, an estimated 40,000 deaths in the United States and 5 million deaths globally result 
from pneumococcal-associated diseases (24, 27, 36). In 2000, over 800,000 (~11%) deaths and 
14.5 million cases of IPDs occurred in children (27). Primarily effecting children (<5 years of 
age), the elderly population (>65 years of age), and immunocompromised individuals, 
pneumococcus is one of the leading causes of morbidity and mortality worldwide despite recent 
advances in antibiotic therapy and vaccinations (24, 27, 36).  
  Pneumococcus produces a variety of virulence factors that contribute to its infectivity 
and colonization including toxin pneumolysin (PLY), surface antigens, and the capsular 
polysaccharide (23, 36). The distinctive structure of the capsular polysaccharide differentiates 
the various STs among S. pneumoniae, as well as stimulates a specific host antibody response 
(23, 36). The pneumococcal capsule is one of the most important virulent factors associated with 
IPDs (23, 36). The role of the capsule provides antiphagocytic activity, prevents degradation 
from the host complementary defense mechanism, initiates colonization onto mucosal surfaces, 
and provides antibiotic resistance (23, 36).  People in high-risk groups (i.e. children <5 years, the 
elderly >65 years, immunocompromised individuals, and those with specific polysaccharide 
antibody deficiency syndrome) do not produce antibodies against the PnPs antigens (30, 36).  Of 
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the ≥90 different PnP STs identified, only 20 STs account for nearly 90% of IPDs that lead to 
hospitalization (12, 21, 36). Encapsulated pneumococcus has shown to be 105 times more 
virulent compared to unencapsulated strains (2).  
 Pneumovax 23 (PN23; Merck, Whitehouse Station, NJ) is a multivalent PnPs vaccine 
comprised from 23 highly purified PnPs of S. pneumoniae STs. PN23 PnP STs; STs 1, 2, 3, 4, 5, 
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20 22F, 23F, and 33F account 
for 88% of the most prevalent and invasive S. pneumoniae STs known to cause IPDs (6, 21). The 
Advisory Committee on Immunization Practices (ACIP) recommends PN23 vaccinations to 
individual’s aged ≥65 years and ≤5 years of age (21). In clinical studies, PN23 has shown to be 
effective against S. pneumoniae hospital-acquired IPDs and penicillin-resistant IPDs (21). 
However, immune responses for each pneumococcal STs vary extensively among individuals, 
with age being a major factor (6, 21, 30). Individuals may exhibit different immune responses, if 
at all, to specific PN23 pneumococcal STs (6, 21, 30). Children ≤5 years of age respond to 
approximately 50% of the PN23 STs, whereas individual’s ≥6 years of age respond to about 70% 
of the PN23 STs (6, 21, 30). Thus far, no studies have evaluated the immunological antibody 
(IgG) response of the 23-valent, PN23, PnP STs vaccine when simultaneously administered with 
F1/V plague vaccine and influenza (Flu) vaccine, two vaccines known to elicit high IgG 
responses. This study is to determine the host IgG immune response of the 23-valent, PN23, 
pneumococcal capsular polysaccharide serotypes using a simian (vervet monkey) model with 
various age groups (9-11 years, 19-23 years, and 25-26 years). This study will also analyze and 
determine which age group elicits a stronger immune response towards the 23-valent PnPs STs 
by comparing pre- and post-vaccination serum samples. 
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Literature Review 
Streptococcus pneumoniae 
Streptococcus pneumoniae is a cocci-cell shaped pathogen that grows in pairs or chains 
(2, 33, 36). A thick peptidoglycan layer characterizes S. pneumoniae, resulting in Gram-Positive 
staining reaction (2, 36). Pneumococcus is alpha-hemolytic, causing partial lyses of red blood 
cells (RBCs), useful for diagnosis and identification of clinical and research samples. Clinically 
relevant pneumococcal organisms are non-motile, non-spore forming, non-acid fast, and possess 
a capsular polysaccharide (33, 36). IPDs occur when pneumococcus crosses the mucosal tissues 
in the nasopharynx and enter the blood stream causing infections such as bacteraemia and sepsis 
(2, 26, 36). Meningitis may also occur when the pathogen enters the blood stream and crosses the 
blood brain barrier (2, 26, 36).  Pneumonia may follow inhalation of S. pneumoniae-containing 
respiratory droplets (2, 26, 36). 
Luminex Immunoassay 
 The Luminex immunoassay, first described by Lal et al. (2005) is an Enzyme-linked 
Immuno Sorbent Assay (ELISA)-based flow cytometric system used to simultaneously measure 
all antibody production for all antigens or analytes. The Luminex immunoassay uses minimal 
volume (≤10 µl) of serum samples and dilutions, without the requirements of growing the 
bacteria, in a single assay (5, 6, 28, 29, 30). The ELISA was adopted as the standard assay for 
PnPs-antibody testing by the World Health Organization (WHO) Advisory Committee (30). The 
WHO Advisory Committee requires 12-14 individual ELISA assay for each PnPs STs and serum 
sample (30). Unlike an ELISA, the Luminex immunoassay can evaluate and analyze the possible 
antibody-analyte interactions as well as the cross-reactivity of desired antibodies within in the 
serum (5, 6, 28, 29, 30). The Luminex immunoassay overall is less time-consuming, less 
 18 
laborious, less expensive, and offers a wider dynamic range then compared to ELISA methods 
(30).  Figure 5 depicts the schematic representation of the Luminex immunoassay principle.  
Materials and Methods 
Vervet Serum Samples 
 The Meningitis and Vaccine Preventable Diseases Branch (MVPDB), Division of 
Bacterial Diseases (DBD) at the CDC in Atlanta, GA, in collaboration with Wake Forest 
University, supplied the pre- and post-vaccinated vervet serum samples with pre-categorized age 
groups (9-11 years, 19-23 years, and 25-26 years). 
Study Design 
 The purpose of this study was to analyze the antibody production of the 23-valent, PN23, 
PnPs vaccine using a vervet (n=10) model with varied age distribution; 9-11 years (n=5), 19-23 
years (n=3), and 25-26 years (n=2). The vervet model was used due to immunological 
similarities to humans. Each subject was vaccinated simultaneously with three, single dose, 
individual vaccines; F1/V plague vaccine, Flu vaccine, and Pneumovax 23 vaccine. Serum was 
collected prior and post vaccinations. IgG serum production was measured using the Luminex 
system (Luminex 200, Luminex, Austin, TX). 
Multiplexed Luminex Pneumococcal Anti-Capsular IgG Capture Assay 
Multiplex (23-plex) pneumococcal anti-capsular IgG capture assay was performed based 
on previous methods with modifications (Lal et al., 2005). Twenty-three purified PnPs STs (i.e. 
ST 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20 22F, 23F, 
and 33F) were purchased from the American Type Culture Collection (ATCC) (Manassas, Va.). 
Briefly, PnPs (Ps, ATCC, Manassas, VA) were conjugated to poly-L-lysine (PLL, Sigma, St. 
Louis, MO) (30).  The PLL-Ps was covalently conjugated to carboxylate-modified microspheres 
(Luminex, Austin, TX) using a two-step carbodiimide reaction (18, 30). PLL-Ps beads for 23 
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PnP ST (2500 beads/serotype in 25µl volume) and sera samples (25µl /well) were transferred to 
96-well MV multi-screen filter plate and incubated at room temperature (RT) for 30 minutes 
with 150 rpm agitation. Plates were rinsed three times with wash buffer (1X PBS containing 
0.05% Tween 20 and 0.2% newborn bovine serum albumin; NBBS, Sigma, St. Louis, MO), 50µl 
/well of biotin-anti monkey-IgG (43R-IG021BT; Fitzgerald, Acton, MA) was added to each 
well, and the plates incubated at RT for 30 minutes with 150 rpm agitation. Plates were then 
washed three times in wash buffer, streptavidin-PE (50µl/well) was added to each well, and the 
plates incubated at RT for 30 minutes with 150 rpm agitation. Plates were washed three times in 
wash buffer, the beads were resuspended in 130µl /well, and data acquired in a Luminex reader 
(Luminex 200, Luminex, Austin, TX) with Masterplex CT software suite (MiraiBio, South San 
Francisco, CA) and expressed as AU/ml (Median Fluorescent Intensity (MFI) x standard dilution 
factor). 
Three post-vaccination sera (1171, 1232 and 1414) that had a high AU/ml signal (>50% 
increase over baseline) for PnPs ST specific IgG (STs 3, 4, 6B, 7F, 9V, 14, 18C, 19F, and 23F) 
of a previous study were combined to generate the vervet reference standard (VV2011). The 
VV2011 dilution curve was generated by plotting median fluorescence intensity (MFI) against 
the dilution factor. Arbitrary units (AU) for PnPs ST specific IgG values was calculated (AU = 
MFI × dilution factor) and assigned to VV2011 for each ST. The VV2011 reference standard 
was included on each assay plate in duplicate and the PnP ST specific IgG values (AU/ml) for 
vervet serum samples were computed using Masterplex QT (MiraiBio, South San Francisco, 
CA). 
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Figure 5. Pneumococcal Polysaccharide Multiplexed Luminex Immunoassay Principle. 
Luminex Assay Principle; (A) Microsphere with capture antibody, (B) Capture antibody binds to 
antigen, (C) Biotinylated detection antibody binds to capture antibody, (D) Streptavidin-PE binds 
to biotinylated detection antibody, (E) Microsphere identification and reporter quantity 
determined by microsphere and detection antibody specific laser detector using a Luminex 
Instrument. 
 
Results 
Vervet Immune Response 
 Table 1 shows the antibody levels specific for the 23 PnP serotypes in serum samples 
obtained from the vervets, n=10, pre- and post-vaccination. The IgG antibody response to the 
STs varied considerably among the vervets; however, all vervet samples (n=10) did have an 
increased IgG response to at least three or more of the PnPs STs after vaccination (Table 2.) One 
subject (vervet serum sample 1414) had an antibody response (≥50% increase over baseline) to 
all 23 PnPs STs in the vaccine. Thirty percent (n=3) of the animals had an antibody response to 
>10 (43.5%) PnPs STs. Seventy percent (n=7) animals had an antibody response to ≥3 - ≥10 
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(≥13.0 - ≥43.5%) PnPs STs. A robust (≥5/10 animals) antibody response was seen in nine 
(39.1%) PnPs STs; (ST4, ST7F, ST8, ST9N, ST11A, ST15B, ST17F, ST19F, and ST20). 
Age-Wise Distribution Analysis 
 Age is often one of the most important factors for the efficacy of vaccines or treatments, 
which applies to the PN23 vaccine (2, 26, 36). The age-wise analysis of the PnPs is shown in 
Table 3. One or more vervets the 9-11 age group mounted an antibody response to all 23 PnPs 
ST tested. The average IgG response in PnPs STs for age group 9-11 years (n=5) was 9.8 
(42.6%). Seventeen (73.9%) of the PnPs STs elicited an antibody response in all subjects in the 
19-23 age group (n=3), while failing to respond to PnPs; ST5, ST6B, ST9V, ST14, ST22F, and 
ST23F. Subjects within the 25-26 age group (n=9) produced antibody to 18 (78.2%) of the 23 
PnPs STs (ST1, 2, 3, 4, 7F, 9N, 9V, 10A, 11A, 12F, 15B, 17F, 18C, 19A, 19F, 20 22F, and 23F). 
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Table 1. Immunoglobulin G Concentrations in Vervet Serum Samples Before and After Pneumococcal Vaccine for 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay.* 
Vervet Serum Sample Number 
PnPs 
STs 
1099  1171  1202  1220  1232 
Before After Pa   Before After Pa   Before After Pa   Before After Pa   Before After Pa 
1 5.68 24.93 ≤.001b  0.62 0.60 .621  0.867 2.69 ≤.001
 b  8.35 6.85 ≤.001
b c  4.81 2.69 ≤.001
b c 
2 3.45 17.43 .024 b   1.83 1.17 .081   1.54 1.25 .638   6.89 4.21 .246   137.09 101.81 .011
 b c 
3 28.38 35.55 .032 b  1.08 1.08 >.99  .89 0.95 .345  6.03 3.53 ≤.001
b c  6.87 6.19 .270 
4 1.81 6.13 ≤.001b   2.37 7.42 ≤.001b   1.37 3.43 .012 b   6.00 3.63 .014 b c   24.01 15.49 .01 b c 
5 39.50 6.65 ≤.001b c  22.17 18.38 ≤.001
b c  6.60 0.54 ≤.001
 b c  58.38 3.81 ≤.001
b c  85.40 5.25 ≤.001
b c 
6B 254.01 177.03 ≤.001b c   3.69 3.50 0.525   2.31 7.88 ≤.001 b   15.70 16.20 .498   89.92 36.29 ≤.001b c 
7F 216.86 997.41 ≤.001b  15.87 683.33 ≤.001
b  81.14 204.80 ≤.001
 b  25.57 80.31 ≤.001
b  62.69 
138.1
5 ≤.001
b 
8 7.90 23.45 ≤.001b   4.73 7.49 .012 b   1.50 9.73 ≤.001 b   288.26 135.43 .004 b c   93.53 67.58 .021 
9N 5.37 14.83 ≤.001b  2.72 67.51 ≤.001
b  2.77 3.56 .096  6.68 5.34 .024
 b c  29.96 20.68 ≤.001
b c 
9V 6.85 10.06 .025 b   3.31 1.25 ≤.001b c   3.31 1.13 .002 b c   5.87 1.52 ≤.001b c   92.56 34.96 ≤.001b c 
10A 9.50 15.89 ≤.001b  2.62 1.49 ≤.001
b c  140.42 36.17 ≤.001
 b c  114.48 93.37 .003
 b c  22.99 11.24 .002
 b c 
11A 1035.05 1318.71 .021 b   163.68 407.46 ≤.001b   6.94 2.63 ≤.001 b c   9.60 11.02 .020 b   36.16 38.84 0.15 
12F 1.00 1.96 ≤.001b  0.25 0 >.99  0.12 0 >.99  3.25 3.36 .477  3.74 1.42 ≤.001
b c 
14 2.75 2.88 .478   2.37 1.38 ≤.001b c   2.62 1.50 ≤.001 b c   2.87 1.63 ≤.001b c   105.54 48.04 ≤.001b c 
15B 3.95 74.08 ≤.001b  0.87 7.64 ≤.001
b  1.31 7.97 ≤.001
 b  5.02 6.22 .038
 b  14.05 24.40 ≤.001
b 
17F 4.15 14.83 ≤.001b   2.62 7.19 ≤.001b   1.63 21.36 ≤.001 b   10.41 35.67 ≤.001b   12.62 19.71 ≤.001b 
18C 677.47 842.55 ≤.001b  14.68 14.75 >.99  9.62 7.13 .021
 b c  29.68 15.45 ≤.001
b c  108.07 61.95 .002
 b c 
19A 141.22 186.33 ≤.001b   9.71 15.17 ≤.001b   10.53 8.39 ≤.001 b c   84.17 40.83 ≤.001b c   33.10 35.03 .417 
19F 32.61 178.63 ≤.001b  7.25 25.31 ≤.001
b  6.56 80.80 ≤.001
 b  25.83 52.21 ≤.001
b  148.20 98.88 .004
 b c 
20 6.00 7.41 .016 b   14.49 22.17 ≤.001b   2.61 1.69 .004 b c   11.64 11.23 .630   24.52 16.93 ≤.001b c 
22F 1.50 1.88 0.20  2.56 0.38 ≤.001
b c  2.68 1.38 .018
 b c  5.50 1.67 ≤.001
b c  8.06 1.81 ≤.001
b c 
23F 6.30 9.68 ≤.001b   2.12 0.38 ≤.001b c   2.10 0.38 ≤.001 b c   3.93 0.63 ≤.001b c   42.10 24.10 ≤.001b c 
33F 16.02 12.02 ≤.001b c   3.22 3.61 .122   1.48 0.35 .006 b c   18.85 8.75 ≤.001b c   30.35 13.42 ≤.001b c 
Continue Overleaf 
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Table 1. Immunoglobulin G Concentrations in Vervet Serum Samples Before and After Pneumococcal Vaccine for 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay* (continued). 
PnPs 
STs 
Vervet Serum Sample Number 
1305  1311  1414  1417  1444 
Before After Pa   Before After Pa   Before After Pa   Before After Pa   Before After Pa 
1 2.719 1.60 .015 b c  7.63 17.57 ≤.001
b  4.12 66.44 ≤.001
b  3.45 2.00 .032
 b c  27.95 12.21 ≤.001
b c 
2 71.71 32.31 .016 b c   15.84 15.43 .789   91.32 1463.81 ≤.001b   1.63 2.35 .205   1.04 1.70 .021 b 
3 2.00 1.85 .475  3.17 2.65 .022
 b c  6.20 191.37 ≤.001
b  2.36 3.39 .006
 b  4.62 2.38 ≤.001
b c 
4 14.13 11.27 .329   2.37 5.54 ≤.001b   102.25 3244.28 ≤.001b   1.31 3.21 ≤.001 b   6.71 5.29 .044 b c 
5 48.44 3.92 ≤.001b c  54.74 13.58 ≤.001
b c  99.97 232.88 ≤.001
b  45.48 7.60 ≤.001
 b c  150.86 8.82 ≤.001
b c 
6B 38.29 16.08 ≤.001b c   97.56 45.44 ≤.001b c   44.59 1278.26 ≤.001b   6.31 4.72 .013 b c   23.16 8.73 ≤.001b c 
7F 27.90 112.69 ≤.001b  447.10 526.16 ≤.001
b  63.41 1461.20 ≤.001
b  37.17 93.83 ≤.001
 b  47.45 67.69 ≤.001
b 
8 37.15 68.35 ≤.001b   3.12 3.32 .366   26.76 1362.25 ≤.001b   1.62 1.42 .649   30.53 11.54 ≤.001b c 
9N 7.43 7.47 .973  4.56 5.28 .071
 b  57.20 2097.60 ≤.001
b  8.38 11.48 ≤.001
 b  421.32 2950.44 ≤.001
b 
9V 33.84 14.61 .011 b c   5.30 5.55 .693   65.95 1888.59 ≤.001b   6.37 3.42 .008 b c   9.35 5.56 ≤.001b c 
10A 30.17 26.36 .007 b c  8.28 9.02 .280  40.89 1098.40 ≤.001
b  66.26 153.46 ≤.001
 b  560.84 1060.89 ≤.001
b 
11A 14.77 42.70 ≤.001b   1041.56 576.45 ≤.001b c   1080.58 1551.47 ≤.001b   509.36 716.40 ≤.001 b   146.86 233.68 ≤.001b 
12F 1.85 1.42 .10  2.15 5.65 ≤.001
b  10.04 74.73 ≤.001
b  0.70 0.45 .055  7.98 3.55 ≤.001
b c 
14 39.76 23.60 ≤.001b c   3.00 1.38 .031 b c   55.86 2058.26 ≤.001b   2.37 1.25 ≤.001 b c   3.18 1.75 .055 
15B 7.27 77.96 ≤.001b  3.52 8.94 ≤.001
b  13.81 578.89 ≤.001
b  3.55 9.90 ≤.001
 b  16.79 15.10 .039
 b c 
17F 29.02 553.11 ≤.001b   13.43 19.98 ≤.001b   30.92 367.25 ≤.001b   125.60 124.08 .843   25.28 17.44 ≤.001b c 
18C 57.37 115.02 ≤.001b  33.81 28.78 .026
 b c  142.14 1976.83 ≤.001
b  8.49 42.30 ≤.001
 b  21.31 16.19 ≤.001
b c 
19A 23.14 20.54 .184   120.55 239.13 ≤.001b   63.10 359.71 ≤.001b   82.75 74.08 .023 b c   327.95 141.50 ≤.001b c 
19F 66.41 50.19 ≤.001b c  363.54 767.33 ≤.001
b  94.64 1773.04 ≤.001
b  17.29 46.23 ≤.001
 b  22.54 46.29 ≤.001
b 
20 5.75 2.42 ≤.001b c   7.47 13.78 ≤.001b   250.83 1676.80 ≤.001b   75.86 128.73 ≤.001 b   17.21 8.63 ≤.001b c 
22F 2.50 0.25 .004 b c  2.25 0.25 ≤.001
b c  94.18 3098.31 ≤.001
b  1.37 0.25 ≤.001
 b c  2.10 0.38 ≤.001
b c 
23F 15.54 7.54 ≤.001b c   2.75 2.00 .181   54.47 1585.88 ≤.001b   2.95 0.38 ≤.001 b c   5.27 2.43 ≤.001b c 
33F 13.83 5.56 ≤.001b c   125.76 105.68 .020 b c   22.13 469.21 ≤.001b   36.95 56.97 ≤.001 b  53.45 27.18 ≤.001
b c 
a P values for the comparisons of vervet serum samples before and after PN23 vaccine for 23 PnPs STs statistically significantly 
difference between before and after vaccination (P<.05). c Statistically significantly difference between pre- and post vaccination that 
did not produce immunological response to PnPs. * IgG concentrations are given as Arbitrary Units (median fluorescence intensity x 
dilution factor) per milliliter. 
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Table 2. Vervet Immune Response to 23 Pneumococcal Polysaccharide Serotypes Determined by Multiplexed Luminex Assay. 
 
Vervet Serum 
Sample No. 
PnPs Serotype Total (%) 
1 2 3 4 5 6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F  
1099 b ++ ++ + ++ - - ++ ++ ++ + ++ + ++ - ++ ++ + + ++ + + ++ - 19 (82.6) 
1171 d - - - ++ - - ++ ++ ++ - - ++ - - ++ ++ - ++ ++ ++ - - - 10 (43.5) 
1202 d ++ - - ++ - ++ ++ ++ + - - - - - ++ ++ - - ++ - - - - 9 (39.1) 
1220 d - - - - - - ++ - - - - - - - + ++ - - ++ - - - - 4 (17.4) 
1232 d - - - - - - ++ - - - - - - - ++ ++ - - - - - - - 3 (13.0) 
1305 c - - - - - - ++ ++ - - - ++ - - ++ ++ ++ - - - - - - 6 (26.0) 
1311 c ++ - - ++ - - - - - - - - ++ - ++ + - ++ ++ ++ - - - 8 (34.8) 
1414 d ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 23 (100) 
1417 c - + + ++ - - ++ - + - ++ + - - ++ - ++ - ++ ++ - - ++ 12 (52.2) 
1444 b - ++ - - - - + - ++ - ++ ++ - - - - - - ++ - - - - 6 (26.1) 
All (10) 4 4 3 6a 1 2 9a 5a 6a 2 4 6a 3 1 9a 8a 4 4 8a 5a 2 2 2 100 (43.5) 
 
 (++) Increase in immune response (≤50%). (+) Increase in immune response (20% - 49%). ( - ) Increase in immune response 
(≤19%). a Robust Immune response to pneumococcal polysaccharide (PnPs) serotype in vervet serum samples (≥5/10 animals). 
 b Age group 25-26 years. c Age group 19-23 years. d Age group 9-11 years. 
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Table 3. Age-Wise Analysis for Vervet Serum Samples. 
 
Age 
(Years) 
No. 
of Subjects 
PnPs STs Count: 
(%)* 
Total 
(%)** 
1 2 3 4 5 6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F  
9-11b 5 
2 1 1 3 1 2 5 3 3 1 1 2 1 1 5 5 1 2 4 2 1 1 1 49 
(4.08) (2.04) (2.04) (6.12) (2.04) (4.08) (10.2) (6.12) (6.12) (2.04) (2.04) (4.08) (2.04) (2.04) (10.2) (10.2) (2.04) (4.08) (8.16) (4.08) (2.04) (2.04) (2.04) (42.6) 
19-23c 3 
1 1 1 2 0 0 2 1 1 0 1 2 1 0 3 2 2 1 2 2 0 0 1 26 
(3.85) (3.85) (3.85) (7.69) - - (7.69) (3.85) (3.85) - (3.85) (7.69) (3.85) - (11.54) (7.69) (7.69) (3.85) (7.69) (7.69) - - (3.85) (37.7) 
25-26d 2 
1 2 1 1 0 0 2 1 2 1 2 2 1 0 1 1 1 1 2 1 1 1 0 25 
(4) (8) (4) (4) - - (8) (4) (8) (4) (8) (8) (4) - (4) (4) (4) (4) (8) (4) (4) (4) - (54.3) 
All 10 
4 4 3 6a 1 2 9a 5a 6a 2 4 6a 3 1 9a 8a 4 4 8a 5a 2 2 2 100 
(4) (4) (3) (6) (1) (2) (9) (5) (6) (2) (4) (6) (3) (1) (9) (8) (4) (4) (8) (5) (2) (2) (2) (43.5) 
 
a Immune response to PN23, PnPs STs in vervet serum samples (≥50%). b Age group 9-11 year vervet samples (serum 1171, 
serum 1202, serum 1220, serum 1232, and serum 1414). c Age group 19-23 year vervet samples (serum 1305, serum 1311, and 
serum 1417). d Age group 25-26 year vervet samples (serum 1099 and serum 1444). ( - ) indicates no response. * Percent given for 
specific serotype within age group. ** Percent given for total serotype in age group. 
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Figure 6. Geometric Mean Concentrations of Vervet Immune Response to 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay. 
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Figure 6. Geometric Mean Concentrations of Vervet Immune Response to 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay (continued). 
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Figure 6. Geometric Mean Concentrations of Vervet Immune Response to 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay (continued). 
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Figure 6. Geometric Mean Concentrations of Vervet Immune Response to 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay (continued). 
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Figure 6. Geometric Mean Concentrations of Vervet Immune Response to 23 Pneumococcal 
Polysaccharide Serotypes Determined by Multiplexed Luminex Assay (continued). 
Geometric mean concentrations (GMC) of pre- and post-vaccination of PN23 pneumococcal 
polysaccharide serotypes for Vervet Serum Samples: (A) 1099, (B) 1171, (C) 1202, (D) 1220, 
(E) 1232, (F) 1305, (G) 1311, (H) 1414, (I) 1417, and (J) 1444. IgG concentrations are given as 
Arbitrary Units (median fluorescence intensity x dilution factor) per milliliter. All experiments 
were performed in triplicate.  
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Discussion 
 Responsible for over one million deaths in children under the age of five alone, S. 
pneumoniae-associated diseases remains one of the leading causes of morbidity and mortality 
throughout the world (37). The high morbidity and mortality rates among high-risk populations 
(i.e. children ≤five years of age; immunocompromised, asthmatic, or asplenic individuals; the 
elderly ≥65 years; and individuals in the developing world) are due to the inability to produce 
effective host antibodies against the PnPs (24, 27, 36, 37). Pneumococcus is an opportunistic 
pathogen that colonizes the mucosal epithelium in the nasopharynx of humans (37). The 
organism becomes pathogenic under host stress where it crosses the mucosal epithelium and 
enters the blood stream (37). External colonization and internal penetration by pneumococcus are 
determined by a multitude of factors including receptor-ligand interactions, receptor-ligand 
avidity and affinity, bacterial strain or ST, presence of a capsule, and previous exposure (37).  
The pneumococcal capsular polysaccharide interferes with the host’s ability to effectively carry 
out complement-opsonization activity, therefore, protecting pneumococcus against phagocytosis 
(9, 36). Additionally, the pneumococcal surface protein A (PspA) binds to the C3 complement 
factor, inhibiting the host’s complement immune response and block opsonization (9, 36). PspA 
also protects the pneumococcus from the bactericidal properties of the apolactoferrin enzyme 
(36). 
Recent studies indicated that approximately thirty-seven percent of children under the age 
of five years are colonized with pneumococcus, with rates increased (57%) in crowded 
conditions (i.e. as schools, parks, and hospitals) where exposure to contaminated aerosolized 
respiratory droplets occurs more frequency (37). Exposure to pneumococcus in 
immunocompetent individuals induces type-specific anticapsular antibodies to PnPs STs, 
whereas high-risk populations lack the ability to elicit effective T-cell independent responses 
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against individual PnPs STs (9). The unresponsiveness to PnPs results in local infections and 
IPDs such as otitis media, bacteremia, meningitis, pneumonia, and sepsis, contributing to the 
high mortality rate around the world (9, 36, 37). Although there have been advancement in the 
development of anticapsular polysaccharide vaccines (PN23) against S. pneumoniae, the 
mortality rate is still a global issue especially among the developing world (9, 37). This high 
mortality rate may be due to the unpredictable host immune response against individual PnPs 
STs of the 23-valent, PN23 vaccine (5, 6, 21, 37). PN23 primarily benefits healthy individuals, 
who can produce effective type-specific antibodies, but does not elicit high efficacy, if at all, 
among the high-risk populations (21, 36, 37). Furthermore, the anticapsular antibody response 
among the very young and very old, differ dramatically due to naïve and weak immune systems, 
respectively (6, 37). The STs within PN23 account for approximately 90% of the most common 
IPDs; therefore, a consistent high-efficacy vaccine is needed (12, 21, 36).   
The present study was conducted to determine if subjects, vervet monkeys, administered 
simultaneously with F1/V and Flu vaccine, known to elicit high IgG immune responses, would 
increase the efficacy rate as well as induce higher PnPs ST-specific IgG antibodies against the 
given PN23 vaccine. Additionally, this study analyzed and compared the PN23 ST-specific 
immune response against different age groups ranging; 9-11 years, 19-23 years, and 25-26 years. 
Serum sample levels were collected pre- and post-vaccination and the total IgG antibody 
responses were analyzed. All subjects measured displayed an increased response to at least three 
or more PnPs STs but did not respond equally to a specific ST. We observed a significant 
immune response, ≥50% increase over baseline, among the STs in the majority (≥5) of subjects, 
subject 1414 responded to all serotypes. These results suggest that simultaneous administration 
of the F1/V, Flu, and PN23 vaccines does not necessarily elicit an overall increased response to 
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the total amount of STs among hosts. However, the STs that elicited an immune response were 
significantly increased, over the baseline, after vaccination.  
The age group, 9-11 years, had one or more subjects respond to all 23, PN23, PnPs STs. 
The age-wise analysis of vervets in the 19-23 age range did not produce an immune response to 
PnPs STs; ST5, ST6B, ST9V, ST14, ST22F, and ST23F. Subjects within the age group 25-26 
years produced an immune response towards PnPs STs; ST1, 2, 3, 4, 7F, 9N, 9V, 10A, 11A, 12F, 
15B, 17F, 18C, 19A, 19F, 20 22F, and 23F, failing to respond to five STs. These results indicate 
that the subjects, 9-11 years, and subjects, 25-26 years, displayed slightly higher (11%) immune 
responses then the age group 19-23 years. Furthermore, the 25-26 year subjects had a 17% 
increase over the age group 19-23 years (Table 3). The antibody titers among high-risk 
populations are lower and therefore are at a greater risk for developing S. pneumoniae-associated 
diseases, whereas healthy population antibody titers are higher and more protective (21).  
The information gathered in this study is important for understanding the importance of 
anti-capsular polysaccharide vaccines among age distributions as well as determining if multiple 
vaccines will affect the immune response against S. pneumoniae. Although the immune response 
towards individual PnPs STs remains inconsistent among individual subjects, the overall baseline 
antibody response increased significantly toward some STs. The youngest (9-11 years) and 
oldest (25-26 years) age groups displayed stronger immune responses, which is essential for 
protection against pneumococcal infections. Therefore, the combination of F1/V, Flu, and PN23 
vaccine is a good model for developing a vaccine treatment that elicits high-efficacy and long-
lasting immunity in high-risk populations. Future studies may seek to further understand the 
molecular immunology interplay between the host and pathogen following the administration of 
PN23, F1/V, and Flu vaccines, for the advancement in vaccine technology and pneumococcal 
prevention.  
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CHAPTER 4. CONCLUSION 
 My involvement at the CDC in Atlanta, GA, and Mulago Hospital in Kampala, Uganda, 
provided me with further insight and appreciation into the dynamic nature of respiratory 
infectious diseases, especially their ability to advantageously adapt and survive in different host 
species. Seeing firsthand how a single disease can cause devastation from individual health to an 
entire economy, I was able to more fully appreciate the efforts of multi-disciplinary health 
professionals and researchers. 
 My time spent at Mulago hospital allowed me to study the significance of zoonotic 
tuberculosis in a densely populated city where the interactions between cattle and humans occurs 
frequently. The high interface between hosts contributes to Mycobacterium bovis diversity, and 
its impact on everyday life, especially among dairy cattle owners. Due to the limited disease 
surveillance in developing countries, the exact number of M. bovis associated tuberculosis in 
livestock and humans is unknown and often misdiagnosed. Because livestock plays such a vital 
economic and social role to the livelihood of individuals in developing countries, it is imperative 
to increase the awareness and control of zoonotic tuberculosis.  
 I was also able to appreciate the implications and importance of vaccine development 
against respiratory infectious diseases, specifically S. pneumoniae in different age groups. The 
experience at the CDC allowed me to study the immunological effect of multiple vaccines, F1/V 
plague vaccine, Flu vaccine, and PN23, against the 23 PnPs STs in the given PN23 vaccine. We 
observed that younger (9-11 years) and older (25-26 years) vervet monkeys display a slightly 
better host immune response compared to subjects in the age range of 19-23 years. This is 
particularly important in high-risk individuals (i.e. children ≤5 years, the immunocompromised, 
and the elderly ≤65 years) that are unable to produce effective antibodies (IgG) against 
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pneumococcal serotypes. Additionally, due to the high morbidity and mortality rates in high-risk 
populations, especially children, advancement in vaccine technology is desirable. 
The current vaccines against zoonotic BTB (BCG) and pneumococcus (PN23) lack the 
ability to induce high efficacy rates and lifelong immunity. Because different strains of STs of 
bacteria within a species induce the immune response differently, the research conducted in my 
presented studies will provide further insight into the important of microbial diversity and its 
ability to independently affect the host immune system.  
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